Pharnext’s PXT-864 shows promise in Parkinson’s disease
10 November 2015 | By Victoria White
In preclinical studies, researchers showed that PXT-864, a combination of baclofen and acamprosate, improved multiple endpoints associated with the development and progression of Parkinson's disease...